Feed BIOR
BI

Biora Therapeutics, Inc. BIOR · OTC

$0.22 +0.00% (+$0.00)

Summary

26 / 100 · Bulios Score

What speaks for it

  • It earns 232 USD a year on every 100 USD of invested capital.
  • It bought back its own shares for $11.3M in the last fiscal year, 1,132% of its market value.

What to watch

  • Revenue fell by 96% a year over the last 3 years.
  • The company made a loss over the last 12 months.
  • It missed profit estimates 5 times in the last 8 quarters.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive

The company made a loss over the last 12 months, so there is no profit to set the price against.

Valuation in detail

Is it growing?

It is shrinking

Revenue (USD)

  • Analyst estimate

Revenue fell by 96% a year over the last 3 years.

Growth in detail

Does it make money?

Income figures for the last 12 months are not available.

Profitability in detail

Is it financially healthy?

Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

No analyst has published a price target.

100% of the analysts recommend buying.

Analysts in detail

What does it earn on?

By product

This revenue breakdown is on the way.

By region

This revenue breakdown is on the way.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy